Affimed develops TandAbs and Trispecific Abs for substantially increasing the efficacy and extend the therapeutic window by three proprietary platforms
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
October 3, 2014 12:08 PM
Advances in Cancer Research
Volume 121, 2014, Pages 67–124 DOI: 10.1016/B978-0-12-800249-0.00002-0
Therapeutic Cancer VaccinesJeffrey Schlom, , James W. Hodge, Claudia Palena, Kwong-Yok Tsang, Caroline Jochems, John W. Greiner, Benedetto Farsaci, Ravi A. Madan, Christopher R. Heery, James L. Gulley
Krishan Maggon 's comment,
July 16, 2014 11:24 AM
thanks a lot, I think this is an important development and a big vote of confidence from big pharma in Cellectis CAR and bioengineered T cells. Great day for French R&D and start up companies in Immunotherapy.
Krishan Maggon 's comment,
July 16, 2014 11:26 AM
I wonder why the total number of visitors and page view remains too low. I think it is the absence from the USA market of Scoop it?
Gilbert C FAURE's comment,
July 16, 2014 12:05 PM
what are you refereeing to? I will send you the draft of a summary for a meeting Science&You next year where I want to submit a talk or a session about curation. Check your e-mail to-morrow.
|
Krishan Maggon 's curator insight,
November 6, 2014 2:43 AM
Immunology and Cell Biology advance online publication 4 November 2014; doi: 10.1038/icb.2014.93 Bispecific T-cell engagers for cancer immunotherapyAmelia M Huehls1, Tiffany A Coupet1 and Charles L Sentman1 1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA Correspondence: Professor CL Sentman, Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH 03756, USA. E-mail:charles.sentman@dartmouth.edu Received 17 August 2014; Revised 29 September 2014; Accepted 29 September 2014
Krishan Maggon 's curator insight,
September 24, 2014 8:40 AM
International Immunopharmacology Volume 21, Issue 2, August 2014, Pages 396–405 DOI: 10.1016/j.intimp.2014.04.026 |
Early stage mab company, lead product AFM 13 for HL in Phase II trials.